Homepage > Company > Media > Pharma News > 2017 > Senator McCaskill drafts bill in response to Allergan patent maneuver

Senator McCaskill drafts bill in response to Allergan patent maneuver

NEW YORK (Reuters) - Democratic U.S. Senator Claire McCaskill on Thursday said she drafted a bill stating that tribal sovereign immunity cannot be used to block U.S. Patent and Trademark Office review of a patent.

Drugmaker Allergan Plc made a deal to transfer some of its patents to a Native American tribe two weeks ago in order to shield them from review.

McCaskill’s response follows a bipartisan U.S. House of Representatives committee decision to investigate the deal earlier this week and previous calls by Democratic Senators for a probe.

“Any thinking person would look at what this company did and say, ‘That should be illegal.’ Well, I agree,” McCaskill said in a statement. “Congress never imagined tribes would allow themselves to be used by pharmaceutical companies to avoid challenges to patents, and this bill will shut the practice down before others follow suit.”

Allergan was not immediately available for comment.

Allergan said last month that it was transferring patents on its blockbuster dry eye medication Restasis to New York’s Saint Regis Mohawk Tribe, which agreed to exclusively license them back to the company in exchange for ongoing payments.

The Tribe issued a statement expressing outrage at McCaskill’s move and accused the senator of engaging in double standards. It said the proposed legislation “specifically targets Indian tribes, yet exempts state universities and other sovereign governments engaged in the very same IPR (inter partes review) process.”

Allergan has argued that the legal maneuver is aimed at removing administrative patent challenges through inter partes review by the U.S. Patent Trial and Appeal Board, and not challenges in federal court. The drugmaker said it believes that the patents should not be subject to the IPR process - which Allergan has called flawed and broken - because of the tribe’s sovereign immunity.

The company still faces a challenge to the patents in federal court.

Additional reporting by Bill Berkrot in New York; Editing by David Gregorio

October 5, 2017

http://www.reuters.com/

Read also

Newly discovered chemical reactions may explain the origin of life

Exactly how inanimate molecules came to life is one of science’s most enigmatic mysteries.

Genentech Inks Licensing Deal With Kiniksa Pharmaceuticals

Genentech has inked a licensing and development deal with Bermuda-based biotech Kiniksa Pharmaceuticals for the company’s investigational drug vixarelimab.

FDA Considers Splitting Jynneos Vaccine Into Fifths for Monkeypox

The FDA is looking into possibly splitting doses of Bavarian Nordic’s Jynneos vaccine into fifths to inoculate individuals 18 years and older against monkeypox in order to address inadequate supp...

FDA Declines Travere’s Second Attempt at Accelerated Approval for Sparsentan

The FDA has rejected Travere Therapeutics’ application for accelerated approval of its investigational drug sparsentan for treatment of patients with focal segmental glomerulosclerosis, a rare d...